{
  "pmcid": "5058646",
  "sha256": "37a2dfce1a99d48bf72e0d3cbd7f9366c728eda1d983d50097fb66d9502f0a31",
  "timestamp_utc": "2025-11-09T22:45:08.123516+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 9.957500000000003,
    "reading_ease": 42.67083333333338,
    "word_count": 192
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "A Randomised Controlled Trial Comparing HF10 Therapy and Traditional SCS for Chronic Pain"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Participants with chronic intractable pain (VAS ≥5.0/10.0 cm) were randomised 1:1"
      },
      "Participants": {
        "score": 2,
        "evidence": "Participants with chronic intractable pain (VAS ≥5.0/10.0 cm) were randomised 1:1 to receive HF10 therapy or traditional SCS."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomised 1:1 to receive HF10 therapy or traditional SCS."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates the long-term efficacy of 10-kHz high-frequency (HF10) spinal cord stimulation (SCS) compared to traditional low-frequency SCS in treating chronic back and leg pain."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the responder rate, defined as ≥50% reduction in back pain at 3 months."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was stratified by sex and primary pain area, with allocation concealment via centrally administered blocks."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Blinding was not feasible due to therapy differences."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "From June to December 2012, 198 participants were randomised (101 HF10, 97 traditional SCS)."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "198 participants were randomised (101 HF10, 97 traditional SCS)."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "At 24 months, 76.5% of HF10 and 49.3% of traditional SCS participants were responders for back pain (27.2% difference, 95% CI, 10.1%-41.8%; P < .001)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were similar between groups."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT01609972"
      },
      "Funding": {
        "score": 1,
        "evidence": "Funding: Supported by Nevro Corp."
      }
    },
    "total_score": 20,
    "max_score": 25
  }
}